Enliven Therapeutics (ELVN) News Today $20.32 +0.38 (+1.91%) Closing price 08/26/2025 04:00 PM EasternExtended Trading$20.32 0.00 (0.00%) As of 08/26/2025 04:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELVN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual MeetingAugust 25 at 6:20 PM | prnewswire.comInsider Selling: Enliven Therapeutics (NASDAQ:ELVN) Insider Sells 5,000 Shares of StockAugust 22, 2025 | insidertrades.comEnliven Therapeutics (NASDAQ:ELVN) CEO Sells $11,800.00 in StockAugust 21, 2025 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Sold by Lord Abbett & CO. LLCAugust 19, 2025 | marketbeat.comWhat is Lifesci Capital's Estimate for ELVN Q3 Earnings?August 19, 2025 | marketbeat.comLifesci Capital Has Positive Outlook for ELVN Q3 EarningsAugust 18, 2025 | americanbankingnews.comEnliven Therapeutics (NASDAQ:ELVN) Announces Earnings ResultsAugust 15, 2025 | marketbeat.comWe're Not Very Worried About Enliven Therapeutics' (NASDAQ:ELVN) Cash Burn RateAugust 15, 2025 | finance.yahoo.comEnliven Therapeutics, Inc.: Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business UpdateAugust 14, 2025 | finanznachrichten.deEnliven Therapeutics Reports Second Quarter Financial Results and Provides a Business UpdateAugust 13, 2025 | prnewswire.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells 6,667 Shares of StockAugust 12, 2025 | marketbeat.comEnliven Therapeutics Inc. Stock Grades | ELVN | Barron'sAugust 12, 2025 | barrons.comXTX Topco Ltd Takes $430,000 Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)August 10, 2025 | marketbeat.comFederated Hermes Inc. Has $1.36 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)August 7, 2025 | marketbeat.comEnliven Therapeutics (ELVN) to Release Quarterly Earnings on TuesdayAugust 6, 2025 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Given Average Rating of "Buy" by AnalystsAugust 5, 2025 | marketbeat.com19,386 Shares in Enliven Therapeutics, Inc. (NASDAQ:ELVN) Bought by BIT Capital GmbHAugust 4, 2025 | marketbeat.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 3,250 Shares of StockJuly 31, 2025 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Position Trimmed by New York State Common Retirement FundJuly 27, 2025 | marketbeat.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells 12,500 Shares of StockJuly 24, 2025 | marketbeat.comEnliven Therapeutics, Inc. (ELVN) - Yahoo FinanceJuly 22, 2025 | finance.yahoo.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells $281,500.00 in StockJuly 22, 2025 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz Sells 12,500 SharesJuly 21, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Stock Price Up 8.4% - Here's What HappenedJuly 18, 2025 | marketbeat.comEnliven Therapeutics’ Promising Phase 1a/1b Study on ELVN-002 in HER2+ CancersJuly 18, 2025 | tipranks.comEnliven Therapeutics (NASDAQ:ELVN) Shares Down 5.7% - Here's What HappenedJuly 15, 2025 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $22,660.00 in StockJuly 15, 2025 | insidertrades.comBenjamin Hohl Sells 1,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockJuly 14, 2025 | marketbeat.comEnliven Therapeutics Breaks Above 200-Day Moving Average - NasdaqJuly 12, 2025 | nasdaq.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Recommendation of "Buy" from BrokeragesJuly 11, 2025 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 6,667 SharesJuly 9, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Trading 5.4% Higher - What's Next?July 9, 2025 | marketbeat.comQ2 EPS Forecast for Enliven Therapeutics Boosted by AnalystJuly 4, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Shares Up 7.9% Following Analyst UpgradeJuly 2, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Stock Price Expected to Rise, HC Wainwright Analyst SaysJuly 2, 2025 | marketbeat.comBenjamin Hohl Sells 3,250 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockJuly 2, 2025 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 3,250 SharesJuly 1, 2025 | marketbeat.comEnliven Therapeutics’ Promising CML Study: A Potential Game-Changer?June 30, 2025 | tipranks.comEnliven Short Interest Falls To 14-Month Low After Leukemia Trial Data, Goldman Initiates With ‘Buy’June 23, 2025 | msn.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells $277,250.00 in StockJune 18, 2025 | marketbeat.comGoldman Sachs initiates Enliven Therapeutics stock with Buy ratingJune 17, 2025 | investing.comEnliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial DataJune 17, 2025 | msn.comEnliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional SharesJune 16, 2025 | prnewswire.comEnliven Therapeutics (NASDAQ:ELVN) Shares Gap Up Following Analyst UpgradeJune 16, 2025 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Consensus Rating of "Buy" from AnalystsJune 16, 2025 | marketbeat.comRobert W. Baird Issues Positive Forecast for Enliven Therapeutics (NASDAQ:ELVN) Stock PriceJune 16, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Coverage Initiated by Analysts at The Goldman Sachs GroupJune 16, 2025 | marketbeat.comEnliven Therapeutics Announces $200 Mln Offering Of Common Stock, Pre-Funded WarrantsJune 15, 2025 | nasdaq.comEnliven Therapeutics stock falls after pricing capital raise of $200M via securities offeringJune 13, 2025 | msn.comEnliven Therapeutics (NASDAQ:ELVN) Shares Gap Down - Should You Sell?June 13, 2025 | marketbeat.com Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ELVN Media Mentions By Week ELVN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELVN News Sentiment▼0.430.98▲Average Medical News Sentiment ELVN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELVN Articles This Week▼94▲ELVN Articles Average Week Get the Latest News and Ratings for ELVN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Enliven Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Cytokinetics News Today Viking Therapeutics News Today TG Therapeutics News Today Krystal Biotech News Today ACADIA Pharmaceuticals News Today Vaxcyte News Today Ascentage Pharma Group International News Today Arcellx News Today ADMA Biologics News Today Zai Lab News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ELVN) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access